{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T23:10:47Z","timestamp":1694387447897},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,7]]},"DOI":"10.18632\/oncotarget.14324","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T01:27:19Z","timestamp":1482974839000},"page":"10025-10036","source":"Crossref","is-referenced-by-count":4,"title":["Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Chun","family":"Chen","sequence":"first","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingting","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianling","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Union Hospital, FMU, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaole","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Deptartment of Biopharmaceutics, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Li","sequence":"additional","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjuan","family":"Fan","sequence":"additional","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhong","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Union Hospital, FMU, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixian","family":"Wu","sequence":"additional","affiliation":[{"name":"Deptartment of Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Institute of Materia Medica, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"},{"name":"Fuijan Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University (FMU), Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,12,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12038-007-0051-y","article-title":"Heat shock protein 90: the cancer chaperone","volume":"32","author":"Neckers.","year":"2007","journal-title":"J. Biosci"},{"key":"2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.drudis.2011.12.021","article-title":"HSP90 inhibition: two-pronged exploitation of cancer dependencies","volume":"17","author":"Workman.","year":"2012","journal-title":"Drug Discov. Today"},{"key":"3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","article-title":"Hsp90 molecular chaperone inhibitors: are we there yet?","volume":"18","author":"Workman.","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1391.012","article-title":"Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress","volume":"1113","author":"Rosen.","year":"2007","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00001622-200311000-00003","article-title":"Heat shock protein 90","volume":"15","author":"Ivy.","year":"2003","journal-title":"Curr. Opin. Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1074\/jbc.M105568200","article-title":"A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket","volume":"277","author":"Csermely.","year":"2002","journal-title":"J. Biol. Chem"},{"key":"7","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1046\/j.1432-1033.2003.03610.x","article-title":"Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATP-binding site","volume":"270","author":"Csermely.","year":"2003","journal-title":"Eur. J. Biochem"},{"key":"8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0021-9258(18)53939-9","article-title":"ATP induces a conformational change of the 90-kDa heat shock protein (hsp90)","volume":"268","author":"Kahn","year":"1993","journal-title":"J. Biol. Chem"},{"key":"9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Witte","year":"1984","journal-title":"Cell"},{"key":"10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0925-5710(95)00361-U","article-title":"BCR\/ABL signal transduction","volume":"61","author":"Broxmeyer.","year":"1995","journal-title":"Int. J. Hematol"},{"key":"11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Baltimore","year":"1990","journal-title":"Science"},{"key":"12","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Van Etten","year":"1999","journal-title":"J Exp Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2174\/138161213804143617","article-title":"Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development","volume":"19","author":"Shiotsu.","year":"2013","journal-title":"Curr. Pharm. Des"},{"key":"15","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/10428190290021371","article-title":"Heat shock protein 90-antagonist destabilizes Bcr-Abl\/HSP90 chaperone complex","volume":"43","author":"Akinaga.","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"16","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Grayzel","year":"2007","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/leu.2008.89","article-title":"Disruption of the Bcr-Abl\/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin","volume":"22","author":"Wen","year":"2008","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.4161\/cc.6.18.4722","article-title":"Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors","volume":"6","author":"Li.","year":"2007","journal-title":"Cell Cycle"},{"key":"19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","article-title":"Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"290","author":"Pan.","year":"2010","journal-title":"Cancer Lett"},{"key":"20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Rao","year":"2001","journal-title":"Science"},{"key":"21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"Duyster.","year":"2002","journal-title":"Lancet"},{"key":"22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI43605","article-title":"BCR-ABL kinase is dead; long live the CML stem cell","volume":"121","author":"Carroll.","year":"2011","journal-title":"J. Clin. Invest"},{"key":"23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker.","year":"2011","journal-title":"J. Clin. Invest"},{"key":"24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cell.2004.10.010","article-title":"JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells","volume":"119","author":"Weissman.","year":"2004","journal-title":"Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"11842","DOI":"10.1073\/pnas.2034201100","article-title":"Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?","volume":"100","author":"Weissman.","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/187152010790909326","article-title":"Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia","volume":"10","author":"Li.","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"key":"27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Li.","year":"2009","journal-title":"Nat Genet"},{"key":"28","first-page":"337","article-title":"Establishment of an imatinib resistant cell line K562\/G01 and its characterization","volume":"25","author":"Yang.","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"29","first-page":"3241","article-title":"Geldanamycin and its 17-allylamino-17- demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction","volume":"63","author":"O\u2019Dwyer.","year":"2003","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/mol.65.1.235","article-title":"Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines","volume":"65","author":"O\u2019Dwyer","year":"2004","journal-title":"Mol. Pharmacol"},{"key":"31","first-page":"3312","article-title":"Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents","volume":"6","author":"Benjamin","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"10536","DOI":"10.1158\/0008-5472.CAN-05-1799","article-title":"Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin","volume":"65","author":"Boyapalle","year":"2005","journal-title":"Cancer Res"},{"key":"33","first-page":"3256","article-title":"Charles Erlichman","volume":"7","author":"Toft","year":"2008","journal-title":"Cisplatin Abrogates the Geldanamycin-induced Heat Shock Response. Mol Cancer Ther"},{"key":"34","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90","volume":"100","author":"Sawyers.","year":"2002","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.leu.2404533","article-title":"Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines","volume":"21","author":"Melo.","year":"2007","journal-title":"Leukemia"},{"key":"36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1078-0432.CCR-13-3317","article-title":"Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells","volume":"21","author":"Wu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Burrows.","year":"2003","journal-title":"Nature"},{"key":"38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/aps.2013.180","article-title":"Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro","volume":"35","author":"Xu.","year":"2014","journal-title":"Acta Pharmacologica Sinica"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T04:35:27Z","timestamp":1658291727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.14324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,28]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,7]]}},"alternative-id":["14324","28036294"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.14324","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,28]]}}}